- Home
- DTST vs CMMB Comparison
DTST vs CMMB Comparison
Compare DTST & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTST
- CMMB
- Stock Information
- Founded
- DTST 2001
- CMMB 2004
- Country
- DTST United States
- CMMB Israel
- Employees
- DTST N/A
- CMMB N/A
- Industry
- DTST EDP Services
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- DTST Technology
- CMMB Health Care
- Exchange
- DTST Nasdaq
- CMMB Nasdaq
- Market Cap
- DTST 28.2M
- CMMB 23.0M
- IPO Year
- DTST N/A
- CMMB N/A
- Fundamental
- Price
- DTST $3.53
- CMMB $1.16
- Analyst Decision
- DTST
- CMMB Strong Buy
- Analyst Count
- DTST 0
- CMMB 2
- Target Price
- DTST N/A
- CMMB $8.50
- AVG Volume (30 Days)
- DTST 29.6K
- CMMB 182.0K
- Earning Date
- DTST 08-13-2025
- CMMB 08-20-2025
- Dividend Yield
- DTST N/A
- CMMB N/A
- EPS Growth
- DTST N/A
- CMMB N/A
- EPS
- DTST 0.02
- CMMB N/A
- Revenue
- DTST $25,219,312.00
- CMMB N/A
- Revenue This Year
- DTST $12.57
- CMMB N/A
- Revenue Next Year
- DTST $9.29
- CMMB N/A
- P/E Ratio
- DTST $149.84
- CMMB N/A
- Revenue Growth
- DTST N/A
- CMMB N/A
- 52 Week Low
- DTST $2.93
- CMMB $0.87
- 52 Week High
- DTST $6.53
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- DTST 49.28
- CMMB 38.60
- Support Level
- DTST $3.33
- CMMB $1.17
- Resistance Level
- DTST $3.56
- CMMB $1.20
- Average True Range (ATR)
- DTST 0.13
- CMMB 0.05
- MACD
- DTST 0.02
- CMMB 0.00
- Stochastic Oscillator
- DTST 70.00
- CMMB 16.46
About DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.